https://doi.org/10.4081/reumatismo.2019.1153
Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease
Accepted: 17 July 2019
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Behçet’s disease is a chronic autoinflammatory disorder that usually presents with recurrent oral and genital ulcers, uveitis, skin lesions and arthritis. Any organ, however, can be involved and in a subgroup of patients the large vascular lesions are the predominant feature (vasculo-Behçet disease). We report a case of a 27-yearold man with Behçet’s disease who developed Budd-Chiari syndrome while on immunosuppressive therapy. Infliximab resulted in a rapid and total clinical remission. Literature data have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab can suppress disease activity but there is no long-term experience on tapering and/or discontinuation of treatment under clinical remission. Our case supports the use of infliximab in vasculo-Behçet patients.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- Y. Ragab, M. Nabih, I. Aly, A. Kamal, M. A. Abd-Allah, R. El-Refai, Y. Emad, A. El-Naggar, N. El-Shaarawy, J.J. Rasker, Magnetic resonance imaging features of hip disorders in an Egyptian pediatric population , Reumatismo: Vol. 67 No. 2 (2015)
- F. Paparo, E. Fabbro, G. Ferrero, R. Piccazzo, M. Revelli, D. Camellino, G. Garlaschi, M.A. Cimmino, Imaging studies of crystalline arthritides , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- S. Barsotti, E. Cioffi, A. Tripoli, A. Tavoni, A. d’Ascanio, M. Mosca, R. Neri, The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature , Reumatismo: Vol. 70 No. 2 (2018)
- M. E. Tezcan, Ş. Demir, M. Sargın, M. Aliustaoğlu, B. Göker, Sjögren’s syndrome and mean platelet volume , Reumatismo: Vol. 67 No. 1 (2015)
- A. Notarnicola, G. Lapadula, D. Natuzzi, F. Iannone, Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies , Reumatismo: Vol. 66 No. 3 (2014)
- G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini, Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy , Reumatismo: Vol. 59 No. 1 (2007)
- A. Notarnicola, F. Iannone, G. Lopalco, M. Covelli, G. Lapadula, A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy , Reumatismo: Vol. 65 No. 6 (2013)
- S. Piantoni, L. Andreoli, F. Allegri, P.L. Meroni, A. Tincani, Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease , Reumatismo: Vol. 64 No. 5 (2012)
- C. Botsios, P. Ostuni, S. Todesco, Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience , Reumatismo: Vol. 57 No. 1 (2005)
- M.E. Tezcan, O. Temizkan, A. Ozderya, M. Melikoglu, K. Aydin, M. Sargin, S. Temizkan, Color Doppler analysis of female reproductive vasculature in Behçet’s disease , Reumatismo: Vol. 67 No. 3 (2015)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
